Lyophilised Describes a Process, Not a Molecule

The claim, and what the approved labels say

The sentence circulates in a fixed shape: tirzepatide is a lyophilised powder. It appears on aggregator pages and reference listings with no manufacturer named, no product named and no document cited, phrased as though physical form were a property of the molecule in the way a molecular formula is. The Vialog tirzepatide record logged it as untraceable rather than dropping it. This note records what was checked and what the checking returned.

Two tirzepatide products hold United States approval: Mounjaro under NDA 215866 from 13 May 2022, and Zepbound under NDA 217806 from 8 November 2023, both held by Eli Lilly and Company. Section 11 of each prescribing information carries the same description sentence, recording a clear, colourless to slightly yellow, sterile solution for subcutaneous use. Single-dose pens and vials hold 0.5 mL containing sodium chloride 4.1 mg, sodium phosphate dibasic heptahydrate 0.7 mg and water for injection. Multi-dose presentations add benzyl alcohol, glycerin and phenol. The pH given in both documents is 6.5 to 7.5.

European labelling agrees. The Mounjaro summary of product characteristics gives the pharmaceutical form as solution for injection, clear, colourless to slightly yellow, with disodium hydrogen phosphate heptahydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections as the excipients of the single-dose pen and vial, and that same list plus benzyl alcohol, glycerol and phenol for the multi-dose KwikPen. It gives no pH figure. Neither lyophilised nor freeze-dried occurs anywhere in that document. A PubMed query pairing tirzepatide with lyophilization, lyophilized, lyophilised or freeze-drying returned zero records when it was run for this note on 17 August 2026.

Freezing, sublimation, desorption

Lyophilisation is a unit operation, not a chemical property. It is performed on a formulated aqueous solution already filled into its final container, and it runs in three stages under a cycle designed for that particular product. Tang and Pikal set out in a 2004 process-design review in Pharmaceutical Research how those stages are chosen and what governs each one.

Freezing comes first. The solution is cooled until ice nucleates and grows, which concentrates everything that does not crystallise into a shrinking unfrozen phase. That freeze-concentrated phase vitrifies at a temperature conventionally written Tg prime, which together with the collapse temperature sets the ceiling for the stage that follows. Searles, Carpenter and Randolph showed in 2001 that annealing the frozen product changed ice crystal size, raised the primary drying rate up to 3.5-fold, produced larger and more numerous holes on the cake surface, and made annealed hydroxyethyl starch samples dissolve slightly faster.

Primary drying removes the ice. Chamber pressure is lowered and heat supplied through the shelf so that ice sublimes directly to vapour, while product temperature is held below the collapse temperature so the solid structure survives the loss of the ice that was holding it up. Secondary drying then removes what never froze: water sorbed to the amorphous solid, driven off by desorption at a raised shelf temperature, over a period set by a residual moisture target rather than by the disappearance of visible ice.

Why the operation is applied to peptides at all

Wang's 2000 review in the International Journal of Pharmaceutics gave the rationale as follows: proteins have limited physical and chemical stability, and reaching an acceptable shelf life often requires conversion to a solid form, with lyophilisation the route the review reported as most frequently applied to get them there. The review attributed the gain to the removal of water in two roles at once, as the reagent for hydrolysis of the peptide bond, and as the medium in which partly unfolded chains find one another and aggregate.

The operation is not free of cost. Bhatnagar, Bogner and Pikal separated the stresses arising in the freezing step alone into low temperature, freeze-concentration and ice formation, noting in their 2007 review that freeze-concentration can also facilitate second-order reactions, crystallisation of buffer components, phase separation and redistribution of solutes. Wang's review makes the parallel point about drying stresses. Formulations intended for lyophilisation are composed against those stresses, which is why the contents of a cake are specific to the cycle it was run through.

Nor does drying stop chemistry. Lai and Topp's 1999 review in the Journal of Pharmaceutical Sciences catalogues the reactions that proceed in the solid state, listing deamidation, peptide bond cleavage, oxidation, the Maillard reaction, beta-elimination and dimerisation or aggregation, and identifies temperature, moisture content, excipients and whether the solid is amorphous or crystalline as the modulating factors. Manning and colleagues' 2010 update treats stabilisation in aqueous solution and in the dried state as two regimes to be compared. Drying moves the problem; it does not close it.

The cake is mostly not the drug

A lyophilised cake is a formulated solid, and in the example that follows the active ingredient is a minor part of it by mass. The EGRIFTA SV prescribing information lists, per single-dose vial, tesamorelin 2 mg alongside histidine 0.78 mg, mannitol 20 mg, polysorbate 20 at 0.05 mg and sucrose 10 mg. In the terms of Wang's review these are functional classes rather than actives: mannitol a bulking agent, sucrose a lyoprotectant, polysorbate 20 a surfactant, histidine a buffer. Altering any one of them yields a different physical object.

Bulking agents behave in ways that depend on the process rather than on the molecule beside them. Kim, Akers and Nail measured this for mannitol in 1998: slow freezing of a 10 percent weight-per-volume solution gave a mixture of the alpha and beta polymorphs, fast freezing of the same solution gave the delta form, and fast freezing at 5 percent gave mainly beta. With a non-crystallising cosolute present, crystalline mannitol became detectable by X-ray powder diffraction above a threshold near 30 percent by weight.

Cake appearance is itself a specified attribute rather than a cosmetic one. A 2017 commentary in the Journal of Pharmaceutical Sciences by Patel and colleagues, drawn from formulation groups across several manufacturers, proposes a harmonised nomenclature for departures from a uniform cake and argues that criticality must be judged product by product, since some non-ideal appearances are inherent to the formulation, the presentation and the process. That is a statement about products, not about molecules.

One active ingredient, three registered physical forms

Glucagon carries the same distinction into the registry. The FDA National Drug Code directory lists it in three finished dosage forms under three separate applications. Under NDA 201849 the prescribing information records the dosage form as injection, powder, lyophilized, for solution: a sterile lyophilised white powder in a 3 mL vial with lactose monohydrate 107 mg, held by Fresenius Kabi. Under NDA 212097 the labelling for Gvoke HypoPen, Gvoke PFS and Gvoke Kit, held by Xeris, records an injection, solution: a ready-to-use non-aqueous preparation in which 1 mg of glucagon sits with trehalose dihydrate and sulfuric acid in 209 mg of dimethyl sulfoxide. Under NDA 210134, Baqsimi is a preservative-free nasal powder with betadex and dodecylphosphocholine.

The variation runs finer than that. Tesamorelin is supplied by one manufacturer under one biologics licence application, 022505, in two lyophilised presentations that are not interchangeable. EGRIFTA SV holds 2 mg of tesamorelin per vial in the excipient system described above, and its labelling records that the reconstituted solution is neither frozen nor refrigerated. EGRIFTA WR holds 11.6 mg of tesamorelin per vial with hydroxypropyl betadex 145 mg and mannitol 43.5 mg, and its labelling records a different diluent and a different post-reconstitution storage condition from EGRIFTA SV.

Storage follows the form rather than the peptide. Both tesamorelin labels record pre-reconstitution storage at 20 to 25 degrees C, in the original box, protected from light. The prescribing information for the tirzepatide solutions records refrigerated storage at 2 to 8 degrees C, an unrefrigerated interval of up to 21 days at not more than 30 degrees C for the single-dose pen and vial and up to 30 days for the multi-dose vial and KwikPen, and an instruction not to freeze. The cold-chain relief that lyophilisation is usually invoked to deliver sits, in this comparison, with the cake and not the solution.

Powder in the registry is not powder in a vial

Querying the National Drug Code directory for tirzepatide returns 166 listings, and they separate cleanly. Every listing with a marketing category of NDA and a product type of human prescription drug, 54 across the two applications, has the dosage form injection, solution. Every listing whose dosage form is powder carries the product type bulk ingredient: 46 as bulk ingredient and 24 as bulk ingredient for human prescription compounding. None of those powder entries has a brand name or an application number.

That is the distinction the circulating claim collapses. Tirzepatide drug substance does exist as a powder, registered by thirty-four distinct labellers in the retrieved set, thirty-two once the variant spellings of one company's name are merged, most of them makers of active pharmaceutical ingredient. Drug substance is not a dosage form; it is the material a dosage form is made from, and the directory records only that it is a powder, not the operation by which it was dried. A further 42 listings are injection, solution under the category drug for further processing.

What a physical-form claim has to carry

A molecular formula is a property of a molecule. A CAS number is a property of a substance. A physical form is a property of a manufactured article, and it changes when the manufacturer changes, when the presentation changes, or when the cycle is redesigned, while the molecule stays exactly what it was. These are different kinds of fact, and they cannot be sourced the same way.

The minimum a physical-form claim has to carry, then, is a named product, the company that holds it, and the document that says so: a prescribing information section, a summary of product characteristics, a registry listing. Species, route and sample size are the analogous requirement for a biological finding. For a formulation statement the analogue is product identity, and a formulation claim without it cannot be checked against anything at all.

Applied here the result is short. Tirzepatide as an approved article is a ready-to-use sterile solution in both approved products and both jurisdictions examined, with a pH of 6.5 to 7.5 recorded in the two United States prescribing informations and no pH figure given in the Mounjaro summary of product characteristics. Tirzepatide as a bulk substance is registered as a powder, with no drying method recorded anywhere in that registration. The sentence that the molecule is a lyophilised powder describes neither, names no product, and remains untraceable as circulated. It stays in the ledger marked that way.